Qualigen Therapeutics is focused on the development of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Co.'s primary product candidate, RP-G28, is an orally administered, galacto-oligosaccharide, for the treatment of lactose intolerance (LI). RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting lactose (the sugar found in milk) that reaches the large intestine. Co.'s first prototype LI product, Lactagen, was an alternative LI treatment method with a mechanism of action similar to RP-G28. The QLGN stock yearly return is shown above.
The yearly return on the QLGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the QLGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|